Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ: BGNE )

176.50 +1.78 (+1.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio?
Large-cap stocks saw worst performance last week, including MongoDB, Applovin, CAVA, Super Micro Computer, FTAI, Adobe, Ferguson, Toll Brothers, BeiGene, Omnicom, and Nucor. 
Via Benzinga
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
From BeiGene, Ltd.
Via Business Wire
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
From BeiGene, Ltd.
Via Business Wire
A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts
Via Benzinga
Why Is BeiGene Stock Trading Higher On Wednesday?
BeiGene's Tevimbra receives EU approval for advanced ESCC and G/GEJ cancers, showing significant survival benefits in pivotal Phase 3 trials. 
Via Benzinga
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
From BeiGene, Ltd.
Via Business Wire
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
From BeiGene, Ltd.
Via Business Wire
Expert Outlook: BeiGene Through The Eyes Of 4 Analysts
Via Benzinga
What Analysts Are Saying About BeiGene Stock
Via Benzinga
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
From BeiGene, Ltd.
Via Business Wire
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
From BeiGene, Ltd.
Via Business Wire
BeiGene Mourns Death of Beloved Board Member Donald Glazer
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
From BeiGene, Ltd.
Via Business Wire
US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Best performing large-cap stocks in the past week were mostly USA listed Chinese stocks due to additional stimulus measures to boost China's economy. 
Via Benzinga
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
From BeiGene, Ltd.
Via Business Wire
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
From BeiGene, Ltd.
Via Business Wire
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers. 
Via Benzinga
Exposures Product Safety
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
Via Benzinga
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BeiGene Announces Updates to Commercial Leadership Team
From BeiGene, Ltd.
Via Business Wire
Innovent Bio hopes for plus-sized profits from obesity drug
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival products to gain a market advantage The executive in charge of... 
Via Benzinga
Topics Retirement
Exposures Pension
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.